BioCentury
ARTICLE | Company News

Anesiva, Transcription Factor Therapeutics Inc. deal

June 9, 2008 7:00 AM UTC

Transcription Factor received exclusive, worldwide rights to Anesiva’s NF-kappa B decoy program, including Avrina, for up to $114 million in upfront and milestone payments, plus royalties. Transcript...